On February 2, 2016, the Patent Trial and Appeal Board (PTAB) rejected another petition by generic-drug maker Lannett Holdings, which urged the PTAB to review claims of Finnegan client AstraZeneca’s Zomig nasal spray patent. The PTAB denied the petition for inter partes review (IPR) because it was filed too late–more than a year after Lannett was served a district court complaint asserting that the company had infringed the patent. The week prior, the PTAB handed down a similar ruling against Lannett, finding that its IPR petition for another Zomig patent (asserted in the same litigation) was also time-barred.
Press Release
September 11, 2024
Announcement
September 3, 2024
Announcement
Finnegan and Partner Daniel Chung Recognized by The National Law Journal
September 3, 2024
Press Release
Finnegan Named a “True Trailblazer” for Its Continued Commitment to Mansfield Certification Process
August 16, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.